Subscribe to Newsletter
Business & Regulation Business Practice, Trends & Forecasts

For Patients, Not Profits

Back in January 2018, “Project Rx” was announced – an ambitious initiative to establish a not-for-profit generic drug company. Further exciting details have now emerged (1). The company will be called Civica Rx and will be headed by Martin VanTrieste, former chief quality officer at Amgen and number 2 on The Medicine Maker’s Power List of Industry Influencers (2). More than 120 health organizations – representing a third of national hospitals in the US – have expressed an interest in some sort of participation.

A huge number of generic medicines have been approved in the US, but shortages – and high prices – are still an issue, particularly for sterile, generic medicines considered “foundational” to hospitals (3). The American Society of Health-System Pharmacists has listed hundreds of compounds facing shortages (4) – a clear problem is that demand is outstripping supply.

Van Trieste has described the company as “a public asset with a mission to ensure that generic medications are accessible and affordable.” Leading very much from the front, Van Trieste takes on the new role without compensation.

What are the facts?
  • Civica Rx will be an FDA-approved manufacturer that will either directly manufacture generic drugs or sub-contract manufacturing to reputable contract manufacturing organizations.
  • The company will seek to stabilize the supply of essential generic medicines administered in hospitals. 
  • A secondary goal is to boost competition within the generic market to lower the costs of crucial medicines.
  • 14 hospital-administered generic drugs will be targeted by the company as an initial focus.
  • The first products are expected to be on the market as early as 2019.
Who’s involved?
  • Catholic Health Initiatives 
  • HCA Healthcare 
  • Intermountain Healthcare
  • Mayo Clinic
  • Providence St. Joseph Health
  • SSM Health
  • Trinity Health
  • The US Department of Veterans Affairs
  • The Laura and John Arnold Foundation
  • The Peterson Center on Healthcare
  • The Gary and Mary West Foundation
Receive content, products, events as well as relevant industry updates from The Medicine Maker and its sponsors.
Stay up to date with our other newsletters and sponsors information, tailored specifically to the fields you are interested in

When you click “Subscribe” we will email you a link, which you must click to verify the email address above and activate your subscription. If you do not receive this email, please contact us at [email protected].
If you wish to unsubscribe, you can update your preferences at any point.

  1. P BusinessWire, “Not-for-Profit Generic Drug Company Officially Established, Attracts Interest of More Than 120 Health Organizations,” (2018). Available at Last accessed September, 2018.
  2. The Medicine Maker, 2018 Power List. Available at
  3. S Barlas, “Frustration Over Generic Drug Shortages and Prices Prompts Federal and Private Actions: Health Systems Take Matters Into Their Own Hands, Pharmacy and Therapeutics, 43 (2018).
  4. ASHP, “Drug Shortages List”. Available at Last accessed September, 2018
Related White Papers
Nitrosamines Risk Mitigation: The critical role of excipients and supplier qualification

| Contributed by DFE Pharma GmbH & Co. KG

Performance validation of ScatterX78 against NIST reference materials

| Contributed by Malvern Panalytical

Early stage product development using laser diffraction analysis

| Contributed by Malvern Panalytical

Register to The Medicine Maker

Register to access our FREE online portfolio, request the magazine in print and manage your preferences.

You will benefit from:
  • Unlimited access to ALL articles
  • News, interviews & opinions from leading industry experts
  • Receive print (and PDF) copies of The Medicine Maker magazine